Drug Evaluation in Angina Pectoris
Gianluigi Ardissino · Lionel H. Opie · Stefano Savonitto
joulu 2012 · Developments in Cardiovascular Medicine Kirja 158 · Springer Science & Business Media
E-kirja
262
sivuja
reportArvioita ja arvosteluja ei ole vahvistettu Lue lisää
Tietoa tästä e-kirjasta
Although there are many books on angina, few are devoted to the important problem of how to evaluate drug efficacy in angina pectoris. Drug Evaluation in Angina Pectoris has two fundamental aims: the first is to review the methodological aspects of drug evaluation in stable and unstable angina pectoris; the second is to provide a logical and methodological background for future studies aimed at assessing the ability of medical treatment to improve prognosis.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Arvioi tämä e-kirja
Kerro meille mielipiteesi.
Tietoa lukemisesta
Älypuhelimet ja tabletit
Asenna Google Play Kirjat ‑sovellus Androidille tai iPadille/iPhonelle. Se synkronoituu automaattisesti tilisi kanssa, jolloin voit lukea online- tai offline-tilassa missä tahansa oletkin.
Kannettavat ja pöytätietokoneet
Voit kuunnella Google Playsta ostettuja äänikirjoja tietokoneesi selaimella.
Lukulaitteet ja muut laitteet
Jos haluat lukea kirjoja sähköisellä lukulaitteella, esim. Kobo-lukulaitteella, sinun täytyy ladata tiedosto ja siirtää se laitteellesi. Siirrä tiedostoja tuettuihin lukulaitteisiin seuraamalla ohjekeskuksen ohjeita.
